Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT04806035 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic/Business Decision

Conditions

CLL
SLL
Richter's Transformation
Indolent Lymphoma
Follicular Lymphoma
Marginal Zone Lymphoma
Aggressive Lymphoma
DLBCL
Mediastinal Large B-cell Lymphoma
MCL

Interventions

BIOLOGICAL: TG-1801
BIOLOGICAL: Ublituximab

Sponsor

TG Therapeutics, Inc.